<DOC>
	<DOCNO>NCT00015860</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . STI571 may stop growth leukemia cell . Combining chemotherapy STI571 may kill cancer cell . PURPOSE : Phase I/II trial study effectiveness combination chemotherapy plus STI571 treat patient chronic myelogenous leukemia acute lymphocytic leukemia .</brief_summary>
	<brief_title>STI571 Plus Combination Chemotherapy Treating Patients With Chronic Myelogenous Leukemia Acute Lymphocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose daunorubicin combine imatinib mesylate , vincristine , prednisone patient lymphoid blastic phase chronic myelogenous leukemia Philadelphia chromosome-positive acute lymphoblastic leukemia . - Determine safety regimen patient . - Determine pharmacokinetics regimen patient . - Determine frequency hematologic cytogenetic response patient treat regimen . - Determine duration response patient population treat regimen . - Determine survival patient treat regimen . OUTLINE : This multicenter , dose-escalation study daunorubicin . Patients previously receive imatinib mesylate receive oral imatinib mesylate day 1-35 . Patients previously receive imatinib mesylate least 28 day receive oral imatinib mesylate day 22-35 . All patient receive daunorubicin IV 2-3 minute day 1-3 , vincristine IV 1 minute day 1 , 8 , 15 , 22 , oral prednisone day 1-28 . Patients 5 % residual blast bone marrow day 28 receive second course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos daunorubicin maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . Once MTD determine , additional patient treat recommended phase II dose . PROJECTED ACCRUAL : A maximum 46 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : One follow diagnosis : Chronic myelogenous leukemia lymphoid blast crisis Acute lymphoblastic leukemia ( ALL ) first relapse fail induction No 1 prior course induction chemotherapy Philadelphia chromosomepositive ( Ph+ ) cytogenetic analysis OR bcr/abl translocation fluorescent situ hybridization At least 30 % blast bone marrow Ineligible refuse allogeneic stem cell transplantation Not previously treat imatinib mesylate OR currently receive imatinib mesylate stable disease 2 bone marrow biopsy least 2 week apart PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : See Disease Characteristics Hepatic : Bilirubin le 3 time upper limit normal ( ULN ) ALT AST less 3 time ULN Renal : Creatinine le 2 time ULN Cardiovascular : No New York Heart Association class III IV cardiac disease Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception least 2 week study female patient least 3 month study male patient PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics No prior allogeneic bone marrow peripheral blood stem cell transplantation At least 48 hour since prior interferon alfa Chemotherapy : See Disease Characteristics At least 24 hour since prior hydroxyurea At least 6 week since prior busulfan Concurrent hydroxyurea anagrelide severe leukocytosis thrombocytosis allow Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify Other : No prior therapy blast crisis except hydroxyurea No prior salvage reinduction therapy Ph+ ALL At least 4 week since prior investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2003</verification_date>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
</DOC>